Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus | Zendy

Cecilia T. Costiniuk | Zendy; Edward J. Mills | Zendy; Curtis Cooper | Zendy

Open Access

Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus

Author(s) -

Cecilia T. Costiniuk,

Edward J. Mills,

Curtis Cooper

Publication year - 2008

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2008/725702

Subject(s) - medicine , nausea , anorexia , weight loss , vomiting , ribavirin , gastroenterology , hair loss , hepatitis c , weight change , hepatitis c virus , immunology , virus , dermatology , obesity

The systemic and cognitive side effects of hepatitis C virus (HCV) therapy may be incapacitating, necessitating dose reductions or abandonment of therapy. Oral cannabinoid-containing medications (OCs) ameliorate chemotherapy-induced nausea and vomiting, as well as AIDS wasting syndrome. The efficacy of OCs in managing HCV treatment-related side effects is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research